| Patient | Frederick Cook |
|---|---|
| Date of birth | 1961-06-10 |
| Identifiers | MRN HR-EX006-SYN; SSN (made up) 000-06-4471 |
| Document date | 2026-11-01 |
| Author | Harriet Okafor-Brandt, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit to establish care after release from prison: history, medication reconciliation, blood pressure, a right carotid bruit, re-entry screening for hepatitis C, tuberculosis and HIV, mood and social needs, and a vascular neurology referral. Concerns: He worries that people will recognize him and that his conviction and the disputes over his claims will follow him to every landlord and employer; He wants to stay well enough to finish his memoirs, and he does not want to depend on anyone. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydrochlorothiazide 25 mg tablet, one tablet by mouth each morning | once daily in the morning | Oral route | 2026-07-21 to 2026-09-29 | completed | S |
| Amlodipine 5 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-07-21 | active | S |
| Atorvastatin 40 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-07-21 | active | S |
| Aspirin 81 mg delayed-release tablet, one tablet by mouth daily | once daily | Oral route | 2026-07-21 | active | S |
| Losartan 50 mg tablet, one tablet by mouth daily | once daily | Oral route | 2026-09-29 | active | S |
| Colchicine 0.6 mg tablet: two tablets at once, one more an hour later, then one tablet twice a day until the flare settles, for up to a week | 1.2 mg, then 0.6 mg an hour later, then 0.6 mg twice daily for up to a week | Oral route | 2026-09-08 to 2026-09-13 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Resting twelve-lead electrocardiogram: sinus rhythm, 72 per minute, normal axis and intervals, no left ventricular hypertrophy by voltage, no Q waves | 2026-07-07 to 2026-07-07 | completed | S |
| Duplex ultrasound of both carotid arteries: right internal carotid peak systolic velocity 165 cm/s, end-diastolic velocity 38 cm/s, internal-to-common carotid ratio 2.6, heterogeneous plaque, consistent with 50 to 69 percent stenosis; left internal carotid peak systolic velocity 96 cm/s with less than 50 percent plaque; both vertebral arteries with antegrade flow | 2026-07-21 to 2026-07-21 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-08-04 to 2026-08-04 | completed | S |
| Transthoracic echocardiogram: normal left ventricular size and wall thickness, no left ventricular hypertrophy, ejection fraction about 60 percent, normal diastolic function for age, mild aortic valve sclerosis without stenosis | 2026-08-18 to 2026-08-18 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-08-04 | Pneumococcal conjugate vaccine (PCV20) | completed | S |
| 2026-08-04 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-08-04 | Tdap vaccine | completed | S |
| 2026-08-04 | Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 1 of 2 | completed | S |
| 2026-09-29 | Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 | completed | S |
| 2026-10-27 | Influenza vaccine, high-dose, trivalent | completed | S |
| 2026-10-27 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1891 to 1899 | Physician on Arctic and Antarctic expeditions in his late twenties and early thirties, including a winter in the Antarctic pack ice in which he treated the crew's scurvy; no illness of his own is recorded in the cited sources | D (CLM-0003, CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | A physician; died of pneumonia when the patient was five | D (CLM-0002) |
| Concern | Status | Evidence |
|---|---|---|
| He worries that people will recognize him and that his conviction and the disputes over his claims will follow him to every landlord and employer | active | S |
| He wants to stay well enough to finish his memoirs, and he does not want to depend on anyone | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 139 on 2026-10-27; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-10-27; Creatinine [Mass/volume] in Serum or Plasma 1.06 on 2026-10-27; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-07-07; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-07-07; Hemoglobin [Mass/volume] in Blood 14.1 on 2026-07-07; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-09-29; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-07-07; Albumin/Creatinine [Mass Ratio] in Urine 18 on 2026-07-07; Cholesterol [Mass/volume] in Serum or Plasma 142 on 2026-09-29; Cholesterol in HDL [Mass/volume] in Serum or Plasma 48 on 2026-09-29; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 2026-09-29; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-09-29; Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay 0.08 on 2026-07-07; Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] corrected for background in Blood 0.02 on 2026-07-07; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 78 on 2026-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-10-27; Urate [Mass/volume] in Serum or Plasma 8.4 on 2026-09-29; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-08-04 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Elevated blood pressure at the first visit, 166/94 mmHg (average of two seated readings), without a previous diagnosis of hypertension; no symptoms; out-of-office confirmation with a week of home readings requested | resolved | confirmed | R03.0 | S — Synthetic presenting finding at re-entry; superseded by the diagnosis at the second visit. |
| Essential hypertension, stage 2, confirmed by home readings averaging 154/90 mmHg; no left ventricular hypertrophy on ECG; urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis made at the second visit. |
| Right carotid bruit heard at the first visit in a man with no symptoms of stroke or transient ischemic attack; carotid duplex ultrasound and vascular neurology consultation requested | resolved | confirmed | R09.89 | S — Synthetic examination finding; superseded by the duplex result at the second visit. |
| Asymptomatic atherosclerotic stenosis of the right internal carotid artery, 50 to 69 percent by duplex ultrasound, with less than 50 percent plaque on the left; no stroke or transient ischemic attack; managed with best medical therapy (blood pressure control, a statin and low-dose aspirin) and yearly duplex surveillance | active | confirmed | I65.21 | S — Synthetic modern diagnosis made at the vascular neurology consultation; not a claim about his real arteries. |
| Recent release from about six years of incarceration: re-entering community life on parole at 65, establishing primary care with no medical records yet received, a rented room, no earned income, and a public reputation he feels as a burden | active | confirmed | Z65.2 | S — Synthetic modern social problem anchored to his documented imprisonment and parole. |
| Acute gout of the right first metatarsophalangeal joint, a first flare seven weeks after starting hydrochlorothiazide, diagnosed clinically (sudden overnight onset, redness, swelling and exquisite tenderness of the big toe, no fever); treated with low-dose colchicine; resolved | resolved | confirmed | M10.271 | S — Synthetic adverse drug effect; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-07-07 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 136-145 mmol/L | Normal | S |
| 2026-07-07 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-07 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-07-07 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-07-07 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-07-07 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 2026-07-07 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-52 U/L | Normal | S |
| 2026-07-07 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-07-07 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | Below 30 | Normal | S |
| 2026-07-07 | Cholesterol [Mass/volume] in Serum or Plasma | 228 | mg/dL | <=199 mg/dL | High | S |
| 2026-07-07 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-07-07 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 148 | mg/dL | Below 100 | High | S |
| 2026-07-07 | Triglyceride [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=149 mg/dL | High | S |
| 2026-07-07 | Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay | 0.08 | {s_co_ratio} | Below 1.00 is nonreactive | Normal | S |
| 2026-07-07 | Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] corrected for background in Blood | 0.02 | [IU]/mL | Below 0.35 is negative | Normal | S |
| 2026-07-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 86 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-07-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-08-18 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 136-145 mmol/L | Normal | S |
| 2026-08-18 | Potassium [Moles/volume] in Serum or Plasma | 3.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-08-18 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-08-18 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 82 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-09-29 | Urate [Mass/volume] in Serum or Plasma | 8.4 | mg/dL | 3.5-7.2 mg/dL | High | S |
| 2026-09-29 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 136-145 mmol/L | Normal | S |
| 2026-09-29 | Potassium [Moles/volume] in Serum or Plasma | 3.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-09-29 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-09-29 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-09-29 | Cholesterol [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-09-29 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 48 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-09-29 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 68 | mg/dL | Below 100 | Normal | S |
| 2026-09-29 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-09-29 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-52 U/L | Normal | S |
| 2026-10-27 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 136-145 mmol/L | Normal | S |
| 2026-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.06 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 78 | mL/min/{1.73_m2} | 60 or more | Normal | S |
| 2026-10-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-08-04 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-07-07 | Body height | 175 | cm | S |
| 2026-07-07 | Body weight | 76 | kg | S |
| 2026-07-07 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-07-07 | Systolic blood pressure | 166 | mm[Hg] | S |
| 2026-07-07 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 2026-07-07 | Heart rate | 74 | /min | S |
| 2026-07-07 | Respiratory rate | 14 | /min | S |
| 2026-07-07 | Body temperature | 36.6 | Cel | S |
| 2026-07-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-07-21 | Body height | 175 | cm | S |
| 2026-07-21 | Body weight | 75.8 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 158 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 72 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.5 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-18 | Body height | 175 | cm | S |
| 2026-08-18 | Body weight | 75.4 | kg | S |
| 2026-08-18 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-08-18 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-08-18 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-08-18 | Heart rate | 70 | /min | S |
| 2026-08-18 | Respiratory rate | 14 | /min | S |
| 2026-08-18 | Body temperature | 36.6 | Cel | S |
| 2026-08-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-29 | Body height | 175 | cm | S |
| 2026-09-29 | Body weight | 75 | kg | S |
| 2026-09-29 | Body mass index (BMI) [Ratio] | 24.5 | kg/m2 | S |
| 2026-09-29 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-09-29 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-09-29 | Heart rate | 68 | /min | S |
| 2026-09-29 | Respiratory rate | 14 | /min | S |
| 2026-09-29 | Body temperature | 36.5 | Cel | S |
| 2026-09-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-10-27 | Body height | 175 | cm | S |
| 2026-10-27 | Body weight | 74.8 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 66 | /min | S |
| 2026-10-27 | Respiratory rate | 14 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-08-04 | Body height | 175 | cm | S |
| 2026-08-04 | Body weight | 75.6 | kg | S |
| 2026-08-04 | Body mass index (BMI) [Ratio] | 24.7 | kg/m2 | S |
| 2026-08-04 | Systolic blood pressure | 144 | mm[Hg] | S |
| 2026-08-04 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-08-04 | Heart rate | 70 | /min | S |
| 2026-08-04 | Respiratory rate | 14 | /min | S |
| 2026-08-04 | Body temperature | 36.6 | Cel | S |
| 2026-08-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-08 | Body height | 175 | cm | S |
| 2026-09-08 | Body weight | 75.2 | kg | S |
| 2026-09-08 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-09-08 | Systolic blood pressure | 142 | mm[Hg] | S |
| 2026-09-08 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-09-08 | Heart rate | 78 | /min | S |
| 2026-09-08 | Respiratory rate | 14 | /min | S |
| 2026-09-08 | Body temperature | 37.2 | Cel | S |
| 2026-09-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-07-07 | New patient visit to establish care after release from prison: history, medication reconciliation, blood pressure, a right carotid bruit, re-entry screening for hepatitis C, tuberculosis and HIV, mood and social needs, and a vascular neurology referral | finished | S |
| 2026-07-21 | Two-week follow-up: home blood pressure readings, carotid duplex ultrasound and vascular neurology consultation, starting treatment | finished | S |
| 2026-08-18 | Six-week review: blood pressure, electrolytes and kidney function on hydrochlorothiazide and amlodipine; statin and aspirin tolerance | finished | S |
| 2026-09-29 | Twelve-week review: blood pressure and lipids after a gout flare on hydrochlorothiazide; switch to losartan | finished | S |
| 2026-10-27 | Sixteen-week review: blood pressure, potassium and kidney function on losartan, mood, social needs and stroke prevention | finished | S |
| 2026-08-04 | Initial preventive physical examination (Welcome to Medicare) | finished | S |
| 2026-09-08 | Same-day sick visit for a painful, swollen right big toe | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Vascular neurology consultation in two weeks, with carotid duplex ultrasound before it, for a right carotid bruit in a man with high blood pressure: degree of stenosis, medical therapy or revascularization, and surveillance | completed | GL-AHA-STROKE-2024, GL-SVS-CAROTID-2021 | S |
| Home blood pressure monitoring twice daily for seven days with a validated upper-arm cuff, to confirm or exclude hypertension before treatment; lower salt, the DASH eating pattern, and daily walking | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Baseline tests: basic metabolic panel, HbA1c, lipid panel, urine albumin-to-creatinine ratio, TSH, hemoglobin and ALT, and a resting ECG; re-entry screening with a hepatitis C antibody, an interferon-gamma release assay for latent tuberculosis, an HIV test and a hepatitis B panel; PHQ-9 | completed | GL-AHA-HTN-2025, GL-CMID-2026, GL-USPSTF-HCV-2020, GL-CDC-HCV-2020, GL-USPSTF-LTBI-2023, GL-CDC-TB-CORR-2006, GL-USPSTF-DEP-2023 | S |
| Re-entry support: a release-of-information request for his prison medical records, a social work referral for housing, Social Security and Medicare enrollment, a low-cost pharmacy plan, and a conversation about shame and reputation, with follow-up of mood at each visit | completed | GL-USPSTF-DEP-2023 | S |
| Two first-line drugs for stage 2 hypertension, hydrochlorothiazide 25 mg and amlodipine 5 mg daily, aiming for below 130/80 mmHg, with sodium, potassium and creatinine in about four weeks | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Best medical therapy for asymptomatic right carotid stenosis of 50 to 69 percent: atorvastatin 40 mg and aspirin 81 mg daily, a lipid panel and ALT in 4 to 12 weeks, blood pressure control, stroke warning signs and calling 911, and a repeat duplex in twelve months | completed | GL-AHA-STROKE-2024, GL-SVS-CAROTID-2021, GL-ESVS-CAROTID-2023, GL-ACC-CHOL-2018, GL-CMID-2026 | S |
| Switch hydrochlorothiazide to losartan 50 mg daily after a drug-induced gout flare, with potassium and creatinine one to two weeks after starting; no urate-lowering drug after a single flare | completed | GL-ACR-GOUT-2020, GL-AHA-HTN-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Office and home blood pressure below 130/80 mmHg by four months | 2026-10-27 | completed | Office 126/76 on amlodipine and losartan | S |
| LDL cholesterol lowered by at least half on a statin | 2026-09-29 | completed | LDL 68 mg/dL, from 148 mg/dL, on atorvastatin 40 mg | S |
| Knows the warning signs of stroke and to call 911 at once | 2026-07-21 | completed | Taught and repeated back the BE FAST signs at the consultation visit | S |
| A stable room, Social Security and Medicare in place, and a health insurance card in hand | 2026-09-29 | completed | Six-month lease on his room; retirement benefits and Medicare approved | S |